Posts

Posted on

Draganfly Issued New Delivery Drone Patent

Variable Center of Gravity Vertical Take-Off and Landing Aircraft
Game Changing for Drone Delivery Vertical

Los Angeles, CA, Jan. 06, 2021 (GLOBE NEWSWIRE) — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, is pleased to announce the awarding of a new patent for a vertical take-off and landing (VTOL) cargo delivery drone with variable center of gravity.

The design is ideal for Beyond Visual Line of Sight (BVLOS) and for transporting goods in hard to reach areas or flight over people at night.

US Patent No. 10,807,707 is an unmanned aircraft system (UAS) configured for both vertical take-off and landing (VTOL) and fixed-wing flight operations includes forward, and aft wing assemblies mounted to the fuselage, each wing assembly including port and starboard nacelles terminating in motor-driven rotors powered by an onboard control system capable of adjusting rotor speeds.

The UAS may transition between a powered-lift VTOL configuration to a winged-flight configuration by shifting its center of gravity forward, pivoting the wing assemblies from a powered-lift position perpendicular to the fuselage to a winged-flight position parallel to the fuselage.

The forward rotor blades may be folded back so that the aft rotors may provide primary thrust for winged flight operations. Onboard attitude sensors may detect rotor or control failures, to which the control system responds by triggering a conversion to the winged-flight configuration for recovery operations.

Draganfly views this patent as an important addition to its robust patent portfolio and believes it to be a core innovation for the industry and the drone delivery vertical.

Draganfly recently announced it had been selected by Coldchain Technology Services, LLC to immediately develop and provide flight services of a robust vaccine delivery payload for use in critical regions for drone delivery of the COVID-19 vaccine.

Coldchain Technology Services, LLC provides comprehensive solutions for healthcare supply chain management for multiple government and commercial clients, including the US Army, the Centers for Disease Control and Prevention, Reserve Component forces, Johnson & Johnson brands, Chicago Department of Public Health, and others and has been leading the deployment of COVID-19 vaccines throughout the United States.

Polaris Market Research estimates the medical drone market at USD 947.6 million by 2027. Facts and Factors estimates the global drone package delivery market was estimated at USD 530 million in 2019 and expected to grow at a compound annual growth rate of 42% from 2020 to 2027.

“With the signing of a signature customer and now this key industry patent we are confident in our role as an important global player in drone delivery space.” said Cameron Chell, CEO of Draganfly. “This showcases Draganfly’s continued focus on IP and highlights the strength and innovation of our engineering team.”

About Draganfly

Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge software and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspections, security, and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.

For more information on Draganfly, please visit us at www.draganfly.com.
For additional investor information, visit https://www.thecse.com/en/listings/technology/draganfly-inc, https://www.otcmarkets.com/stock/DFLYF/overview or https://www.boerse-frankfurt.de/aktie/draganfly-inc.

Media Contact
Arian Hopkins
email: [email protected] 

Company Contact
Email: [email protected]

Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking ‎‎‎‎‎‎information” as ‎defined under applicable Canadian securities laws. Forward-looking statements ‎‎‎‎‎‎and information can ‎generally be identified by the use of forward-looking terminology such as ‎‎‎‎‎‎‎“may”, “will”, “expect”, ‎‎“intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar ‎‎‎‎‎‎terminology. Forward-looking ‎statements and information are based on forecasts of future ‎‎‎‎‎‎results, estimates of amounts not yet ‎determinable and assumptions that, while believed by ‎‎‎‎‎‎management to be reasonable, are inherently ‎subject to significant business, economic and ‎‎‎‎‎‎competitive uncertainties and contingencies. Forward-‎looking statements include, but are not ‎‎‎‎‎‎limited to, statements with respect to the successful utilization ‎and integration of the Company’s technology. Forward-‎‎‎‎looking statements and information are ‎subject ‎to ‎various known and unknown risks and ‎‎‎‎uncertainties, many of which are beyond the ‎ability of ‎the ‎Company to control or predict, that ‎‎‎‎may cause the Company’s actual results, ‎performance or ‎‎achievements to be materially different ‎‎‎‎from those expressed or implied thereby, ‎and are ‎developed ‎based on assumptions about such ‎‎‎‎risks, uncertainties and other factors set ‎out here ‎in, including but not ‎limited to: the potential ‎‎‎‎impact of epidemics, pandemics or other ‎public ‎health crises, including the ‎current outbreak of ‎‎‎‎the novel coronavirus known as COVID-19 ‎on the ‎Company’s business, operations ‎and financial ‎‎‎‎condition, the successful integration of ‎‎technology, the inherent risks involved in the ‎general ‎‎‎‎securities markets; uncertainties relating to ‎‎the availability and costs of financing needed in the ‎‎‎‎‎future; the inherent uncertainty of cost ‎‎estimates and the potential for unexpected costs and ‎‎‎‎expenses, ‎currency fluctuations; regulatory ‎‎restrictions, liability, competition, loss of key ‎‎‎‎employees and other ‎related risks and uncertainties ‎‎disclosed under the heading “Risk Factors“ ‎‎‎‎in the Company’s most ‎recent filings filed with ‎‎securities regulators in Canada on the SEDAR ‎‎‎‎website at www.sedar.com. The ‎Company ‎‎undertakes no obligation to update forward-looking ‎‎‎‎information except as required by ‎applicable ‎‎law. Such forward-looking information represents ‎‎‎‎managements’ best judgment based on ‎‎‎information currently available. No forward-looking ‎‎‎‎statement can be guaranteed and actual ‎‎future ‎results may vary materially. Accordingly, readers ‎‎‎‎are advised not to place undue reliance ‎‎on forward-‎looking statements or information.‎



Posted on

Blink Charging Named to Forbes’ List of America’s Best Small Companies

– Blink’s share price experienced the second highest growth among the 100 High Performance Companies

Miami Beach, FL, Jan. 06, 2021 (GLOBE NEWSWIRE) — Blink Charging Co. (NASDAQ: BLNK, BLNKW) (“Blink” or the “Company”), a leading owner and operator of electric vehicle (EV) charging equipment and services, announced today that Forbes included the Company on its List of America’s Best Small Companies. The list can be accessed online at: https://www.forbes.com/lists/best-small-cap-companies/#77d93e9647db.

“We are honored to have been included on Forbes’ List of America’s Best Small-Cap Companies. All of us at Blink are intently focused on leveraging the opportunities we see to bring accessible and convenient high-speed chargers to the marketplace as EV use continues to grow. It is exciting to be recognized by Forbes, and our inclusion on this list is a testament to the hard work of our employees across our entire organization,” commented Michael D. Farkas, Founder and Chief Executive Officer of Blink. 

While compiling its America’s Best Small-Cap Companies List, Forbes used FactSet data and screened for companies with a market value between $300 million and $2 billion, positive sales growth over the past 12 months, and a share price of at least $5. Excluded from the list were financial institutions, REITs, utilities, limited partnerships, and companies that have been public for less than one year. The rankings were based on earnings and sales growth for the last 12 months and over five years, one-year and 5-year return on equity and 52-week total return. Forbes more heavily weighted the latest-12 month and 1-year data in the rankings. The data was last updated on November 25, 2020.

# # #


About Blink Charging

Blink Charging Co. (Nasdaq: BLNK, BLNKW) is a leader in electric vehicle (EV) charging equipment and has deployed more than 23,000 charging stations, many of which are networked EV charging stations, enabling EV drivers to easily charge at any of the Company’s charging locations worldwide. Blink Charging’s principal line of products and services include its Blink EV charging network (“Blink Network”), EV charging equipment, and EV charging services. The Blink Network uses proprietary, cloud-based software that operates, maintains, and tracks the EV charging stations connected to the network and the associated charging data. With global EV purchases forecasted to rise to 10 million vehicles by 2025 from approximately 2 million in 2019, the Company has established key strategic partnerships for rolling out adoption across numerous location types, including parking facilities, multifamily residences and condos, workplace locations, health care/medical facilities, schools and universities, airports, auto dealers, hotels, mixed-use municipal locations, parks and recreation areas, religious institutions, restaurants, retailers, stadiums, supermarkets, and transportation hubs. For more information, please visit https://www.blinkcharging.com/.

Forward-Looking Statements

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should,” or other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief, or current expectations of Blink Charging and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described in Blink Charging’s periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Blink Charging undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Blink Media Contact 


[email protected]

Blink Investor Relations Contact

[email protected] 
855-313-8187



Posted on

Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer

Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer

Appointment Reflects Progress of Verastem’s RAS Targeted Therapy Development Program

Verastem Recently Initiated Registration-Directed Trials with VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer

BOSTON–(BUSINESS WIRE)–
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of industry veteran Frank Neumann, M.D., Ph.D., as Chief Medical Officer to oversee the Company’s clinical and regulatory strategy and Medical Affairs team.

“Frank brings deep expertise across the full spectrum of clinical and regulatory activities in all stages of Oncology drug development,” said Brian Stuglik, Chief Executive Officer of Verastem Oncology. “His strong industry experience and commitment to urgently addressing the high unmet needs of patients will be critical to delivering novel treatments and establishing the backbone of RAS targeted therapy as we move forward with our registration-directed trials of VS-6766 and defactinib.”

“I am thrilled to be joining Verastem at this time given the encouraging results to date of VS-6766 and defactinib for patients with difficult-to-treat KRAS mutant tumors and the possibility to address limitations seen with other therapeutic approaches,” said Dr. Neumann. “The broad potential of these development programs and the opportunity to further establish Verastem’s scientific and medical leadership is truly energizing.”

Dr. Neumann joins Verastem from bluebird bio where he served as VP, Head of Oncology Clinical Research, Clinical Research Development. In this role, he was responsible for planning and execution of oncology research asset strategies from pre-clinical to Investigational New Drug Application (IND) submissions, across both solid tumor and hematological indications. He has also held various leadership roles at Takeda Pharmaceuticals, including global clinical lead for ICLUSIG® (ponatinib) and medical team lead for NINLARO® (ixazomib). He served as clinical development head for all of Takeda’s cell therapy approaches globally from POC to Phase 1 and was also responsible for various U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) interactions for Takeda’s programs.

Earlier in his career, Dr. Neumann was a member of the oncology medical teams at AstraZeneca and Sanofi-Aventis and was a research scholar at the University of Texas MD Anderson Cancer Center. Dr. Neumann received his medical degree from the Heinrich-Heine University in Duesseldorf, Germany and his Ph.D. from the Rheinische-Friedrich-Wilhelm University in Bonn, Germany. He is Board-Certified in Hematology/Oncology, Internal Medicine, and Palliative Care Medicine and is currently an assistant professor at the Heinrich Heine University in Düsseldorf, Germany.

About VS-6766

VS-6766 is an oral small molecule inhibitor of the RAF/MEK signaling pathway. In contrast to other MEK inhibitors in development, VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. This unique mechanism allows VS-6766 to block MEK signaling without the compensatory activation of MEK that appears to limit the efficacy of other inhibitors.

About Defactinib

Defactinib (VS-6063) is an oral small molecule inhibitor of the FAK and PYK2 signaling pathways that is currently being evaluated as a potential combination therapy for various solid tumors. Verastem has received Orphan Drug Designation for defactinib in ovarian cancer in the U.S., EU and Australia. Preclinical research by Verastem Oncology scientists and collaborators at world-renowned research institutions have described the effect of FAK inhibition to enhance immune response by decreasing immuno-suppressive cells, increasing cytotoxic T cells, and reducing stromal density, which allows tumor-killing immune cells to enter the tumor.1,2

About the VS-6766/Defactinib Combination

RAS mutant tumors are present in about 30% of all human cancers, have historically presented a difficult treatment challenge and are often associated with significantly worse prognosis.3 Challenges associated with identifying new treatment options for these types of cancers include resistance to single agents,3 identifying tolerable combination regimens with MEK inhibitors and new RAS inhibitors in development addressing only a minority of all RAS mutated cancers.

The combination of VS-6766 and defactinib has been found to be clinically active in patients with KRAS mutant tumors. In an ongoing investigator-initiated Phase 1/2 FRAME study, the combination of VS-6766 and defactinib is being evaluated in patients with recurrent low-grade serous ovarian cancer (LGSOC), KRAS mutant NSCLC and colorectal cancer. Updated data from this study presented at the 2nd Annual RAS-Targeted Drug Development Summit in September 2020 demonstrated a 56% overall response rate and long duration of therapy among patients with KRAS-G12 mutant LGSOC.4 Based on an observation of higher response rates seen in NSCLC patients with KRAS-G12V mutations in the study, Verastem is also exploring the role of VS-6766 and defactinib in KRAS-G12V mutant NSCLC. The FRAME study was expanded in August 2020 to include new cohorts in pancreatic cancer, KRAS mutant endometrial cancer and KRAS-G12V mutant NSCLC.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

Forward-Looking Statements Notice

This press release includes forward-looking statements about Verastem’s strategy, future plans and prospects, including statements related to the potential clinical value of the RAF/MEK/FAK combination. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “can,” “promising” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement.

Applicable risks and uncertainties include the risks and uncertainties, among other things, regarding: the success in the development and potential commercialization of our product candidates, including defactinib in combination with VS-6766; the occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis or result in unmanageable safety profiles as compared to their levels of efficacy; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the scope, timing, and outcome of any legal proceedings; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of our product candidates; whether preclinical testing of our product candidates and preliminary or interim data from clinical trials will be predictive of the results or success of ongoing or later clinical trials; that the timing, scope and rate of reimbursement for our product candidates is uncertain; that third-party payors (including government agencies) may not reimburse; that there may be competitive developments affecting our product candidates; that data may not be available when expected; that enrollment of clinical trials may take longer than expected; that our product candidates will experience manufacturing or supply interruptions or failures; that we will be unable to successfully initiate or complete the clinical development and eventual commercialization of our product candidates; that the development and commercialization of our product candidates will take longer or cost more than planned; that we or Chugai Pharmaceutical Co., Ltd. will fail to fully perform under the VS-6766 license agreement; that we may not have sufficient cash to fund our contemplated operations; that we may be unable to make additional draws under our debt facility or obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity, debt financing or otherwise; that we will be unable to execute on our partnering strategies for defactinib in combination with VS-6766; that we will not pursue or submit regulatory filings for our product candidates; and that our product candidates will not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients.

Other risks and uncertainties include those identified under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission (SEC) on November 9, 2020 and in any subsequent filings with the SEC. The forward-looking statements contained in this press release reflect Verastem’s views as of the date hereof, and we do not assume and specifically disclaim any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

References

1 Chénard-Poirier, M. et al. Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma. Journal of Clinical Oncology 2017: 35. 10.1200/JCO.2017.35.15_suppl.2506.

2 ClinicalTrials.gov. Phase I Trial of VS-6063 and RO5126766. (FRAME). Available at: https://clinicaltrials.gov/ct2/show/NCT03875820. Accessed November 24, 2020.

3 Baines, A. T., Xu, D., & Der, C. J. (2011). Inhibition of Ras for cancer treatment: the search continues. Future medicinal chemistry, 3(14), 1787–1808. https://doi.org/10.4155/fmc.11.121

4 Verastem Press Release. Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit. September 16, 2020. Available at: https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-presentation-updated-phase-12-frame. Accessed November 24, 2020.

Investors:

Ajay Munshi

Vice President, Corporate Development

1 781-469-1579

[email protected]

Media:

Lisa Buffington

Corporate Communications

+1 781-292-4205

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Posted on

Konica Minolta Partners with Loadbalancer.org for Workflow and MPS Applications

New Solution Offers Zero Downtime, Improved Performance and Scalability to Enhance Customer Experience

Ramsey, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) — Konica Minolta Business Solutions, U.S.A., Inc. (Konica Minolta), today announced a new distribution agreement with Loadbalancer.org that will enhance customer experience by better distributing application, network and data traffic efficiently and securely, particularly in sectors where zero downtime is critical.

Established in 2003, Loadbalancer.org develops and supplies load balancer and application delivery controller (ADC) products and services, delivering availability and scalability with unbreakable solutions to ensure zero downtime for critical IT applications. Through the partnership, Loadbalancer.org can be integrated with Konica Minolta solutions related to Print and Document Management, as well as Automated Workflow apps. The Loadbalancer.org solution can also be sold in conjunction with the new Konica Minolta Workplace Hub Core or Workplace Hub Smart solutions providing secure fully managed platforms with 24/7 monitoring and management. Users of Konica Minolta Print Management and Workflow Automation applications such as Dispatcher Suite and others will benefit from features such as:

  • Zero downtime – failover print/app servers with no user impact
  • Scalability – add or remove servers from a cluster
  • Optimal performance – spread traffic across multiple servers
  • Resilience – multi-site failover utilizing Global Server Load Balancing (GSLB)
  • Easy maintenance – bring servers off/online at the touch of a button

“What continues to impress us about Loadbalancer.org is their mission to make sure our customers experience uninterrupted uptime, as well as how easily and quickly they are able to develop custom deployment guides for our workflow and print management applications. We are getting that same positive feedback from our solution vendors as well,” said Chris Bilello, Director of Business Development, Konica Minolta. “Because of the existing relationships they had with vendors compatible with our solutions, at the time of launch we will be able to offer their services with a majority of our core office applications.”

“This is a unique partnership because of all the varying solutions Konica Minolta provides and how closely we’ve been able to work with them,” said Roman Humphreys, Partner Development Manager, Loadbalancer.org. “We were able to quickly align to perform extensive testing, build out a lot of resources and create tailored solutions.”

About load balancing

Organizations that depend on mission-critical applications for printing and workflow need a load balanced solution to distribute network traffic across multiple servers. A load balancer offers high availability and reliability, routing traffic to individual servers in the most efficient way while also moving any points of failure to another server to keep things running constantly. By utilizing on-premises or cloud-based servers to handle the workload of an application or workflow, the solution can also increase performance. Using a load balancing appliance, companies can also easily bring servers on and offline to perform maintenance tasks without disrupting users – all of which results in zero downtime. This is especially critical in industries such as healthcare, finance and government.

Visit Konica Minolta online to learn more about its MPS and workflow apps supported by Loadbalancer.org.

About Konica Minolta

Konica Minolta Business Solutions U.S.A., Inc. is reshaping and revolutionizing the Workplace of the Future™ with its expansive smart office product portfolio from IT Services (All Covered), ECM, Managed Print Services and industrial and commercial print solutions. Konica Minolta has been recognized as the #1 Brand for Customer Loyalty in the MFP Office Copier Market by Brand Keys for thirteen consecutive years, and the World Technology Awards recently named the company a finalist in the IT Software category. Konica Minolta, Inc. has been named to the Dow Jones Sustainability World Index for eight consecutive years and has spent three years on the Global 100 Most Sustainable Corporations in the World list. Konica Minolta partners with its clients to give shape to ideas and work to bring value to our society. For more information, please visit us online and follow Konica Minolta on Facebook, YouTube, Linked In and Twitter.

About Loadbalancer.org

Loadbalancer.org ensures zero downtime for its clients’ applications, with solutions that are simple, unbreakable, and designed around customer needs. With almost 20 years’ experience, the company has deployed application delivery controller products and services more than 14,000 times in over 70 countries, complete with a full suite of professional services, and industry-leading levels of pre and after-sales support. For more information, please visit www.loadbalancer.org or follow us on LinkedIn.

# # # # #

Attachment 



Maggie Grande
Konica Minolta Business Solutions U.S.A., Inc.
1-551-500-2659
[email protected]

Posted on

Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer

Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer

-Infinity Planning New, Registration-Enabling Study in Advanced Urothelial Cancer Leveraging Encouraging Data from MARIO-275-

-MARIO-275 Data to be Presented at a Major Medical Meeting in Q1 2021-

-Infinity Provides 2021 Milestones and Financial Guidance-

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today provided an update on MARIO-275, the Company’s randomized, placebo controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced, metastatic urothelial cancer (mUC) over nivolumab monotherapy which is approved in this setting.

“The MARIO-275 study provided Infinity with important insights to shape the future of eganelisib in urothelial cancer,” said Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals. “The data from the 49 patients enrolled in the study are very encouraging. The combination was well tolerated at the 30 mg dose of eganelisib and provided patient benefit relative to the placebo controlled arm on important response rate and progression free survival measures, particularly in urothelial cancer patients with low levels of PD-L1 expression who respond poorly to checkpoint inhibitors alone. We are leveraging the clinical and translational learnings from MARIO-275 in planning a new, registration-enabling study of eganelisib in patients with advanced urothelial cancer. We look forward to presenting our data from MARIO-275, which support our clinical strategy, at a major medical meeting in Q1 2021, with details for our new, planned trial to follow in the coming months after discussions with regulatory authorities.”

Encouraging data including in post-CPI progression and PD-L1 low patients was presented at The Society for Immunotherapy of Cancer (SITC) in November and the San Antonio Breast Cancer Symposium (SABCS) in Q4 2020.

Program Updates and Guidance:

MARIO-275

  • The MARIO-275 Independent Data Monitoring Committee (IDMC) determined that there was a favorable risk/benefit for patients after the successful implementation of a dose reduction from 40mg QD to 30mg QD to reduce the reversible liver enzyme elevations that were reported after the first scheduled MARIO-275 IDMC meeting.
  • Infinity has completed the evaluation of the 49 patients enrolled in the study with encouraging safety, response rate and progression free survival (PFS) data, including in patients with low levels of PD-L1 expression.
  • Infinity will be presenting the MARIO-275 data at a major medical meeting in Q1 2021.
  • As a result of the encouraging data, the Company is planning a new registration-enabling study and will not re-open enrollment in MARIO-275.

MARIO-3

  • Data was presented at SABCS in December which showed the benefit of adding eganelisib to standard of care Tecentriq® and Abraxane® therapy for front-line TNBC patients.
  • Progression-free survival and updated overall response rate data for TNBC will be presented in 1H and 2H of 2021.
  • Renal cell carcinoma data to be presented in 1H 2022.

2021 Financial Guidance

Infinity ended 2020 with approximately $34.1 million in cash and investments (unaudited) and plans to report its fourth quarter and full-year 2020 financial results in March. The Company expects to have cash through 2021 based on its current operating plans, which excludes additional financing or business activities, and excludes a potential $5 million milestone payment from BVF for positive Phase 3 patidegib data and any milestones from, or the sale of the Company’s equity interest in, PellePharm.

About Infinity and Eganelisib

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity’s website at www.infi.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding: the therapeutic potential of eganelisib; plans to present data; plans to not re-open MARIO-275 for enrollment; plans for a registration-enabling study in urothelial cancer; financial guidance; and the Company’s ability to execute on its strategic plans. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. For example, there can be no guarantee that eganelisib will successfully complete necessary preclinical and clinical development phases. Further, there can be no guarantee that any positive developments in Infinity’s product portfolio will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the cost, timing and results of clinical trials and other development activities that may be delayed or disrupted by the COVID-19 pandemic or otherwise; the content and timing of decisions made by the U.S. FDA and other regulatory authorities; Infinity’s ability to obtain and maintain requisite regulatory approvals; unplanned cash requirements and expenditures; development of agents by Infinity’s competitors for diseases in which Infinity is currently developing or intends to develop eganelisib; and Infinity’s ability to obtain, maintain and enforce patent and other intellectual property protection for eganelisib. These and other risks which may impact management’s expectations are described in greater detail under the caption “Risk Factors” included in Infinity’s annual report and quarterly reports filed with the Securities and Exchange Commission (SEC), and in other filings that Infinity makes with the SEC, available through the Company’s website at www.infi.com. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity does not undertake and expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Opdivo® is a registered trademark of Bristol Myers Squibb.

Tecentriq® is a registered trademark of Genentech, Inc.

Abraxane® is a registered trademark of Abraxis BioScience, LLC.

Avastin® is a registered trademark of Genentech, Inc.

Doxil® is a registered trademark of Baxter Healthcare Corporation.

Ashley Robinson

LifeSci Advisors, LLC

617-775-5956

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Oncology FDA Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Posted on

Peet’s Coffee Rings in the New Year with a Lineup of Golden Restorative Beverages

Featuring on-trend Ginger and Turmeric, Peet’s launches new Golden Tonic and returning favorite, Golden Latte

PR Newswire

EMERYVILLE, Calif., Jan. 6, 2021 /PRNewswire/ — After a long 2020 and indulgent holiday season, Peet’s Coffee® is delivering a boost of goodness with ginger and turmeric in its Golden beverage lineup, including a new Golden Tonic and a returning favorite, the Golden Latte. Accompanying the handcrafted beverage offerings are two nourishing warm breakfast frittatas to jumpstart your year as well as the arrival of the annual favorite, Ethiopian Super Natural, that is as fragrantly fruity as it is uniquely rich.

“Not only are we thrilled to bring back our Golden Latte for winter, but we are also proud to introduce our Golden Tonic,” said Patrick Main, Senior Beverage R&D Manager. “Turmeric and ginger continue to grow in demand, particularly in beverages driven by their reputed functional benefits. These beverages highlight the flavorful and fragrant ingredients for a delicious and invigorating beverage to restore after the holidays.”

Restore with Golden Goodness
Crafted with ‘superfood’ ingredients, including ginger and turmeric, the following 2021 winter beverages are handcrafted with restorative spices and ingredients and available across participating Peet’s coffeebars 1/6/2021 to 3/2/2021.


  • Golden Tonic

    (Iced or Hot): Smooth Mighty Leaf® Green Tea Tropical, steamed with a touch of earthy turmeric, joins bright yuzu citrus and warming ginger with a touch of honey for a boost of golden goodness.
  • Golden Latte (Iced or Hot): A touch of turmeric, honey, and warming ginger are steamed with milk before meeting freshly hand-pulled Espresso Forte in the Golden Latte.
  • Peetnik Rewards Exclusive – Golden Chai Latte (Iced or Hot): Bold Mighty Leaf® Masala Chai, aromatic and sweet with warming spices, and perfectly steamed milk get a boost from golden turmeric. Available exclusively to members of the Peetnik Rewards program.

Frittatas: Nourish in the New Year
They say breakfast is the most important meal of the day—and it certainly sets the tone for what lies ahead. To start the New Year off right, Peet’s warm breakfast menu represents a re-entry to more conscious eating with light and savory offerings that feature protein-packed, made without wheat, on-the-go options for all. The new Egg White, Tomato & Feta Frittata and Bacon, Spinach & Swiss Frittata, are the perfect satisfying pick-me-up to nourish you in the New Year, available across participating Peet’s coffeebars 1/6/2021 to 3/2/2021.

  • Egg White, Tomato & Feta Frittata: Egg whites whipped with a blend of Greek yogurt, a touch of cream, and feta. Flecked with chunks of sweet roasted tomatoes and ribbons of kale. Made without wheat.
  • Bacon, Spinach & Swiss Frittata: A returning favorite: cage-free eggs, a blend of Greek yogurt and cream, and gruyere are blended and baked up with spinach, cured bacon, and sweet onion jam. Made without wheat.

“As consumers becoming increasingly focused on making careful dietary choices, we want to provide foods that match their values,” said Lori Fulmer, Senior Food R&D Manager. “We’re excited to unveil our new frittatas which are made without wheat, provide an Excellent Source of protein and deliver an egg white option allowing our customers to satisfying their cravings in a way that meets their needs.”

To learn more, visit peets.com/winter, and order the winter beverages and warm breakfast offerings online for pickup and delivery at pickup.peets.com.

Elevate Your 2021 with Fruity Brilliance
Peet’s single-origin Ethiopian Super Natural is a returning favorite for over 20 years. This dark roast showcases the Hambela region’s most selected coffee and is abundantly fruity and known for its distinctive blueberry notes.

“Presenting a memorable sip in the New Year, our single-origin coffee from Ethiopia is fragrantly fruity, sweet, and full,” said Doug Welsh, Roastmaster, Peet’s Coffee. “With a whiff of white flower, a concentrated dose of dried blueberry, and a shot of candied citron, our dark roast brings to life the finest, most select fruit, freshly harvested and sun-dried in Ethiopia.”

Available now through 3/2/2021, and while supplies last, coffee fans can purchase Ethiopian Super Natural at participating Peet’s coffeebars, as well as at www.peets.com, for $19.95 USD per pound. 


About Peet’s Coffee:

Founded in Berkeley, California in 1966 by Alfred Peet, the “Big Bang of coffee,” Peet’s Coffee® introduced an artisan movement by sourcing the world’s best beans, hand-roasting in small batches, and crafting beverages by hand. With rich, complex, superior quality roasts unlike anything Americans ever tasted before, Peet’s influenced generations of coffee entrepreneurs and connoisseurs. Today, Peet’s is uncompromisingly dedicated to its founding tenets and asserts a strict standard of freshness, ensuring optimum flavor with a team that personally vets the beans and ready-to-drink (RTD) coffee available at 15,000 grocery and convenience stores nationwide. Peet’s operates from the first LEED® Gold certified roastery in the United States and grows its business through retail, grocery, on-premise, and e-commerce channels. For more information, visit www.peets.com. Stay connected to Peet’s: @peetscoffee on Twitter and Instagram and facebook.com/peets.

 

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/peets-coffee-rings-in-the-new-year-with-a-lineup-of-golden-restorative-beverages-301201815.html

SOURCE Peet’s Coffee Inc.

Posted on

Celsius Set to Join S&P SmallCap 600® Index

PR Newswire

BOCA RATON, Fla., Jan. 6, 2021 /PRNewswire/ — (Nasdaq: CELH) Celsius Holdings Inc., maker of the leading global fitness drink, CELSIUS®, today announced that the Company will be added to the S&P SmallCap 600 Index, effective January 07, 2021, prior to the market open. The S&P SmallCap 600 measures the small-cap segment of the U.S. equity market and consists of 600 domestic stocks selected by Standard & Poor’s Index Committee based on certain criteria, such as market capitalization and financial viability.

“We are extremely proud to be included in the S&P SmallCap 600, another significant milestone for the Company,” commented John Fieldly, President and Chief Executive Officer. “With our continued operational performance, we anticipate our shareholders will benefit from the increased market visibility and liquidity going forward. Qualifying for the index reflects the Company’s continued prospects for long-term growth.”


About Celsius Holdings, Inc. 

Celsius Holdings, Inc. (Nasdaq: CELH), is a global company with a proprietary, clinically proven formula for its master brand CELSIUS® and all its sub-brands. A lifestyle fitness drink and a pioneer in the rapidly growing performance energy sector, CELSIUS® has five beverage lines that each offer proprietary, functional, healthy-energy formulas clinically-proven to offer significant health benefits to its users. The five lines include, CELSIUS® Originals, CELSIUS HEAT™, CELSIUS® BCAA +Energy, CELSIUS® On-the-Go, and CELSIUS® Sweetened with Stevia. CELSIUS® has zero sugar, no preservatives, no aspartame, no high fructose corn syrup, and is non-GMO, with no artificial flavors or colors. The CELSIUS® line of products is Certified Kosher and Vegan. CELSIUS® is also soy and gluten-free and contains very little sodium. CELSIUS® is backed by six university studies that were published in peer-reviewed journals validating the unique benefits CELSIUS® provides. CELSIUS® is sold nationally at Target, CVS, Walmart, GNC, Vitamin Shoppe, 7-Eleven, Dick’s Sporting Goods, The Fresh Market, Sprouts and other key regional retailers such as HEB, Publix, Winn-Dixie, Harris Teeter, Shaw’s and Food Lion. It is also available on Amazon, at fitness clubs and in select micro-markets across the country. For more information, please visit: http://www.celsiusholdingsinc.com


Forward-Looking Statements
 

This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of Celsius Holdings’ future results of operations and/or financial position, or state other forward-looking information. In some cases, you can identify these statements by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would,” or similar words. You should not rely on forward-looking statements since Celsius Holdings’ actual results may differ materially from those indicated by forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: general economic and business conditions; our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations affecting our business; and other risks and uncertainties discussed in the reports Celsius Holdings has filed previously with the Securities and Exchange Commission. Celsius Holdings does not intend to and undertakes no duty to update the information contained in this press release.

Investor Relations:

Cameron Donahue

(651) 707-3532
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/celsius-set-to-join-sp-smallcap-600-index-301202030.html

SOURCE Celsius Holdings, Inc.

Posted on

Robert A. Dee Promoted to Assistant Vice President and Controller of American Financial Group, Inc.

Robert A. Dee Promoted to Assistant Vice President and Controller of American Financial Group, Inc.

CINCINNATI–(BUSINESS WIRE)–
American Financial Group, Inc. (NYSE: AFG) is pleased to announce the promotion of Robert (Bob) A. Dee to Assistant Vice President and Controller.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005492/en/

Robert A. Dee (Photo: Business Wire)

Robert A. Dee (Photo: Business Wire)

Mr. Dee joined AFG in 1985 and has held positions of increasing responsibility within the finance and accounting areas during his over 35 years with the Company. In his new role, he will be responsible for oversight of accounting policies and procedures in compliance with generally accepted accounting principles (GAAP) and other applicable regulations and financial reporting to the Securities and Exchange Commission.

Mr. Dee earned a bachelor’s degree in accounting from Xavier University and is a Certified Public Accountant (CPA) in the State of Ohio.

About American Financial Group, Inc.

American Financial Group is an insurance holding company, based in Cincinnati, Ohio with assets of approximately $70 billion as of September 30, 2020. Through the operations of Great American Insurance Group, AFG is engaged primarily in property and casualty insurance, focusing on specialized commercial products for businesses, and in the sale of traditional fixed and indexed annuities in the retail, financial institutions, broker-dealer, and registered investment advisor markets. Great American Insurance Group’s roots go back to 1872 with the founding of its flagship company, Great American Insurance Company.

Diane P. Weidner

Vice President – Investor & Media Relations

513-369-5713

[email protected]

Websites:

www.AFGinc.com

www.GreatAmericanInsuranceGroup.com

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Banking Professional Services Insurance Finance

MEDIA:

Logo
Logo
Photo
Photo
Robert A. Dee (Photo: Business Wire)
Posted on

Vistra Brings World’s Largest Utility-Scale Battery Energy Storage System Online

Flagship of company’s Vistra Zero portfolio will provide affordable, zero-carbon electricity, bolster reliability of California’s power grid

PR Newswire

IRVING, Texas, Jan. 6, 2021 /PRNewswire/ — Vistra (NYSE: VST) today announced that its Moss Landing Energy Storage Facility connected to the power grid and began operating on Dec. 11, 2020. At 300 megawatts/1,200 megawatt-hours, the lithium-ion battery storage system, located on-site at Vistra’s Moss Landing Power Plant in Monterey County, California, will be the largest of its kind in the world. Furthermore, construction is already underway on Phase II, which will add an additional 100 MW/400 MWh to the facility by August 2021, bringing its total capacity to 400 MW/1,600 MWh.

“This is a keystone project and it is important in so many ways – it revitalizes an existing power plant site and utilizes active transmission lines, enhances grid stability, fills the reliability gap created by intermittent renewables, provides emission-free electricity, supports California’s sustainability goals and mandates, significantly benefits the local community, and ultimately provides affordable electricity to consumers,” said Curt Morgan, chief executive officer of Vistra. “A battery system of this size and scale has never been built before. As our country transitions to a clean energy future, batteries will play a pivotal role and the Vistra Moss Landing project will serve as the model for utility-scale battery storage for years to come.”  

Housed inside the power plant’s completely refurbished former turbine building and spanning the length of nearly three football fields, Phase I of the battery system can power approximately 225,000 homes during peak electricity pricing periods. The system is made up of more than 4,500 stacked battery racks or cabinets, each containing 22 individual battery modules, which capture excess electricity from the grid, largely during high solar-output hours, and can release the power when energy demand is at its highest and solar electricity is declining, usually early morning and late afternoon.

Phases I and II of the Vistra Moss Landing Energy Storage Facility are backed up by long-term resource adequacy contracts with Pacific Gas and Electric Company (PG&E).

“We appreciate the strong working relationship we’ve developed with PG&E on multiple projects and look forward to continuing to help meet its resource adequacy requirements and provide clean, reliable, and affordable power to Californians,” Morgan said.

Vistra’s Moss Landing site provides a unique opportunity for extensive future expansion of the battery storage system. With its existing infrastructure and the physical space for potential growth, this world-class industrial-zoned site can support up to 1,500 MW/6,000 MWh of storage capacity should market and economic conditions support it. With the development permit already in place and the site in condition for expansion, Vistra will be able to move quickly when that time comes.

Vistra is a market leader in utility-scale battery energy storage development and commercialization. Its Moss Landing project is the flagship of its 4,000-MW zero-carbon Vistra Zero portfolio, which includes a total of five battery projects in California and Texas:

  • Upton 2 (10 MW/42 MWh) – online December 2018
  • Moss Landing – Phase I (300 MW/1,200 MWh) – online December 2020
  • Moss Landing – Phase II (100 MW/400 MWh) – expected online by August 2021
  • Oakland (36.25 MW/145 MWh) – expected online 2022
  • DeCordova (260 MW/260 MWh) – expected online 2022

Support for Vistra Moss Landing Energy Storage Project

California State Senator John Laird said, “As the largest of its kind in the world, the Vistra Zero Moss Landing Energy Storage Facility will store renewable energy, releasing it when it is needed most. It is meaningful, ambitious projects like these that will help to pave the way to a 100% clean energy future for California and the rest of the world.”


Monterey County Supervisor John M. Phillips said, “When people think about Moss Landing energy, they usually envision the landmark power plant and its two tall smokestacks. In fact, Vistra’s Moss Landing Energy Storage Facility will be the largest battery storage facility of its kind in the world and will provide a tremendous amount of reliable, clean energy. Vistra continues to be an outstanding community partner and reliable steward of the historic Moss Landing Power Plant.”


Electronic MEDIA KIT, including photos, b-roll, interviews, and more, is available here.

About Vistra

Vistra (NYSE: VST) is a leading, Fortune 275 integrated retail electricity and power generation company based in Irving, Texas, providing essential resources for customers, commerce, and communities. Vistra combines an innovative, customer-centric approach to retail with safe, reliable, diverse, and efficient power generation. The company brings its products and services to market in 20 states and the District of Columbia, including six of the seven competitive wholesale markets in the U.S. and markets in Canada and Japan, as well. Serving nearly 5 million residential, commercial, and industrial retail customers with electricity and natural gas, Vistra is the largest competitive residential electricity provider in the country and offers over 50 renewable energy plans. The company is also the largest competitive power generator in the U.S. with a capacity of approximately 39,000 megawatts powered by a diverse portfolio, including natural gas, nuclear, solar, and battery energy storage facilities. In addition, the company is a large purchaser of wind power. The company is currently constructing a 400-MW/1,600-MWh battery energy storage system in Moss Landing, California, the largest of its kind in the world. Vistra is guided by four core principles: we do business the right way, we work as a team, we compete to win, and we care about our stakeholders, including our customers, our communities where we work and live, our employees, and our investors. Learn more about our environmental, social, and governance efforts and read the company’s sustainability report at https://www.vistracorp.com/sustainability/.

Cautionary Note Regarding Forward-Looking Statements
The information presented herein includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on current expectations, estimates and projections about the industry and markets in which Vistra Corp. (“Vistra”) operates and beliefs of and assumptions made by Vistra’s management, involve risks and uncertainties, which are difficult to predict and are not guarantees of future performance, that could significantly affect the financial results of Vistra. All statements, other than statements of historical facts, that are presented herein, or in response to questions or otherwise, that address activities, events or developments that may occur in the future, including such matters as activities related to our financial or operational projections, the potential impacts of the COVID-19 pandemic on our results of operations, financial condition and cash flows, projected synergy, value lever and net debt targets, capital allocation, capital expenditures, liquidity, projected Adjusted EBITDA to free cash flow conversion rate, dividend policy, business strategy, competitive strengths, goals, future acquisitions or dispositions, development or operation of power generation assets, market and industry developments and the growth of our businesses and operations (often, but not always, through the use of words or phrases, or the negative variations of those words or other comparable words of a future or forward-looking nature, including, but not limited to: “intends,” “plans,” “will likely,” “unlikely,” “believe,” “confident”, “expect,” “seek,” “anticipate,” “estimate,” “continue,” “will,” “shall,” “should,” “could,” “may,” “might,” “predict,” “project,” “forecast,” “target,” “potential,” “goal,” “objective,” “guidance” and “outlook”), are forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. Although Vistra believes that in making any such forward-looking statement, Vistra’s expectations are based on reasonable assumptions, any such forward-looking statement involves uncertainties and risks that could cause results to differ materially from those projected in or implied by any such forward-looking statement, including, but not limited to: (i) adverse changes in general economic or market conditions (including changes in interest rates) or changes in political conditions or federal or state laws and regulations; (ii) the ability of Vistra to execute upon the contemplated strategic, capital allocation, and performance initiatives and to successfully integrate acquired businesses; (iii) actions by credit ratings agencies; (iv) the severity, magnitude and duration of pandemics, including the COVID-19 pandemic, and the resulting effects on our results of operations, financial condition and cash flows; and (v) those additional risks and factors discussed in reports filed with the Securities and Exchange Commission by Vistra from time to time, including the uncertainties and risks discussed in the sections entitled “Risk Factors” and “Forward-Looking Statements” in Vistra’s annual report on Form 10-K for the year ended Dec. 31, 2019 and any subsequently filed quarterly reports on Form 10-Q.

Any forward-looking statement speaks only at the date on which it is made, and except as may be required by law, Vistra will not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date on which it is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible to predict all of them; nor can Vistra assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vistra-brings-worlds-largest-utility-scale-battery-energy-storage-system-online-301202027.html

SOURCE Vistra Corp.

Posted on

Brigham Minerals, Inc. Announces Participation in Goldman Sachs Global Energy Conference 2021

Brigham Minerals, Inc. Announces Participation in Goldman Sachs Global Energy Conference 2021

AUSTIN, Texas–(BUSINESS WIRE)–Brigham Minerals, Inc. (NYSE: MNRL) (“Brigham Minerals,” “Brigham,” or the “Company”) today announced that Rob Roosa, Chief Executive Officer, will participate in a panel at the Goldman Sachs Global Energy Conference on January 7th at 3:00 p.m. Central Time.

ABOUT BRIGHAM MINERALS, INC.

Brigham Minerals is an Austin, Texas based company that acquires and actively manages a portfolio of mineral and royalty interests in the core of some of the most active, highly economic, liquids-rich resource basins across the continental United States. Brigham Minerals’ assets are located in the Permian Basin in Texas and New Mexico, the SCOOP and STACK plays in the Anadarko Basin of Oklahoma, the DJ Basin in Colorado and Wyoming, and the Williston Basin in North Dakota. The Company’s primary business objective is to maximize risk-adjusted total return to its shareholders by both capturing organic growth in its existing assets as well as leveraging its highly experienced technical evaluation team to continue acquiring minerals.

At the Company:

Brigham Minerals, Inc.

Blake C. Williams

Chief Financial Officer

(512) 220-6350

Or

For Investor and Media Inquiries:

Lincoln Churchill Advisors

Julie D. Baughman

(512) 220-1500

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Logo
Logo